arrow
S

Samuel A. Funt

Memorial Sloan Kettering Cancer Center
H指数:31
被引数:4,055

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma: a real-world study☆

恩康坦(enfortumab vedotin)和帕博利珠单抗(pembrolizumab)治疗转移性尿路上皮癌后铂类化疗:一项真实世界研究☆

2026-07-240
OAAI
Real-world clinical outcomes of sacituzumab govitecan after prior exposure to enfortumab vedotin in patients with metastatic urothelial carcinoma☆

接受过恩普替尼韦汀治疗后的转移性尿路上皮癌患者中,沙西妥珠单抗戈维他胺的实时临床疗效☆

2025-06-010
OA
Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression

接受恩沃利单抗(EV)单药治疗且未出现疾病进展的转移性尿路上皮癌(mUC)患者的临床结局

2024-09-010
PRE
IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition

改进: 通过大规模验证T细胞识别来预测新表位免疫原性的特征模型

2024-04-034
OAAI
Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience
2023-09-0815
PRE
TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy
2023-08-164
OAAI
Overcoming Barriers to Tumor Genomic Profiling through Direct-to-Patient Outreach
2023-03-022
OA